↓ Skip to main content

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Overview of attention for article published in BMC Cancer, November 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
1 news outlet
patent
4 patents

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
49 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Published in
BMC Cancer, November 2008
DOI 10.1186/1471-2407-8-352
Pubmed ID
Authors

Sean P Dineen, Laura A Sullivan, Adam W Beck, Andrew F Miller, Juliet G Carbon, Roni Mamluk, Henry Wong, Rolf A Brekken

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
Sweden 1 2%
Unknown 46 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 24%
Student > Ph. D. Student 9 18%
Student > Doctoral Student 4 8%
Student > Bachelor 4 8%
Other 4 8%
Other 8 16%
Unknown 8 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 16 33%
Biochemistry, Genetics and Molecular Biology 7 14%
Medicine and Dentistry 7 14%
Engineering 3 6%
Chemistry 3 6%
Other 3 6%
Unknown 10 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2023.
All research outputs
#2,229,037
of 23,549,388 outputs
Outputs from BMC Cancer
#380
of 8,517 outputs
Outputs of similar age
#9,829
of 168,010 outputs
Outputs of similar age from BMC Cancer
#2
of 33 outputs
Altmetric has tracked 23,549,388 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,517 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.